A Study of ERAS-801 in People with Glioblastoma That Came Back After Treatment

Share

Full Title

A Phase 1 Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients with Recurrent Glioblastoma (THUNDERBBOLT-1)

Purpose

The purpose of this study is to find the highest dose of the investigational drug ERAS-801 that can be given safely in people with glioblastoma, a type of brain tumor, that came back despite treatment. ERAS-801 works by blocking the EGFR protein, which sends signals to cells to encourage cancer growth. By blocking EGFR, ERAS-801 may stop the growth and spread of cancer cells. It is taken orally (by mouth). Participants in this study will take ERAS-801 either once or twice a day.

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have recurrent glioblastoma that does not contain a mutation in an IDH gene.
  • Patients must have previously received radiation therapy and temozolomide.
  • The serious side effects of prior treatments must go away before ERAS-801 is given.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr.  Ingo Mellinghoff at 646-888-2766.

Protocol

22-187

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators